
Keywords: OA; osteoarthritis; IL; interleukin-1β; TNF; tumor necrosis factor-α; MMPs; metalloproteinases; NO; nitric oxide; FDA; Drug Administration; EMEA; European Medicines Agency; PG; proteoglycans; iNOS; inducible nitric oxide synthase; TEM; transmission elec